Investigation of Ansun Biopharma dismissed

Ansun BioPharma, a San Diego-based biotech company formerly known as NexBio, says that an investigation by the US Attorney's Office over the misconduct of its former chief executive and chief financial officer has been dismissed.

"We are pleased with the dismissal of the investigation. With new management in place we have made significant progress with our late stage clinical programs for parainfluenza and influenza," noted Ronald Moss, CEO of Ansun Biopharma, adding: "We also have developed a pipeline of therapies against other respiratory viruses such as metapneumovirus and eneterovirus68."

"Ansun had a rough patch with its former CEO and CFO, but it's a company that has never given up doing important work here in San Diego developing anti-viral therapies for unmet medical needs," stated Ansun's general counsel, Mikael Havluciyan. "We were very happy to be able to work with the local US Attorney's Office to help resolve the investigation in a way that made sense not just for the company, but for the national public welfare as well," he explained.